Table 2.
Prognostic Factor Analyses
| Variable | Univariable |
Multivariable |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Treatment arm (RR v MR) | 1.17 | 0.85 to 1.60 | .33 | 1.07 | 0.77 to 1.49 | .68 |
| Age (< 60 v ≥ 60 years) | 0.86 | 0.63 to 1.17 | .34 | 0.89 | 0.61 to 1.30 | .54 |
| Time since diagnosis (< 1 v ≥ 1 year) | 0.83 | 0.48 to 1.41 | .48 | 0.99 | 0.55 to 1.79 | .97 |
| Sex (female v male) | 0.93 | 0.68 to 1.27 | .66 | 0.96 | 0.69 to 1.33 | .80 |
| Histologic grade (1 v 2) | 0.84 | 0.59 to 1.20 | .33 | 0.82 | 0.57 to 1.18 | .29 |
| FLIPI score (intermediate v low) | 1.76 | 1.06 to 2.92 | .03 | 1.71 | 1.01 to 2.87 | .04 |
| FLIPI score (high v low) | 1.57 | 0.94 to 2.61 | .09 | 1.45 | 0.81 to 2.58 | .21 |
Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; MR, maintenance rituximab; RR, re-treatment rituximab.